SGP compared with PBLS: revenue, margins and what each company keeps, and the suppliers and customers both name

SGPSpyGlass Pharma, Inc.

Mkt capRevenueRevenue

PBLSParabilis Medicines, Inc.

Mkt capRevenueRevenue

Compare

SGPSpyGlass Pharma, Inc.

PBLSParabilis Medicines, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

SGP1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+2.26%—

PBLS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−4.65%—

= impliedSGP realized, solidPBLS realized, hatchedOne scale, both sides: full bar = 5%× = |realized| ÷ impliedSource: market data

SGPSpyGlass Pharma, Inc.

36.20▲+6.22%· post 36.21

Mkt cap$1.2BRevenue—

PBLSParabilis Medicines, Inc.

28.58▲+2.50%· post 28.58

ClosedNov 6 '26

Mkt cap$824.8MRevenue$148,000Q2 FY26

Compare

ClosedNov 6 '26

SGPSpyGlass Pharma, Inc.

PBLSParabilis Medicines, Inc.

36.20▲+6.22%post 36.21

Price

28.58▲+2.50%post 28.58

$1.2B

Mkt cap

$824.8M

—

Revenue

$148,000Q2 FY26

SGP36.20▲+6.22%vsPBLS28.58▲+2.50%ClosedNov 6 '26